Vimaisamd plans private-label skincare line after Munich trade show trip

Virginia Carneiro, founder of Miami-area clinic Vimaisamd, traveled to Munich for CosmeticBusiness 2026 to meet European manufacturers and begin developing a patient skincare line. The products are expected to launch in late 2026 and could give the clinic a proprietary take-home offering tied to its non-surgical treatments. Why it matters: - Vimaisamd is aiming to extend treatment results beyond the clinic with a proprietary skincare line for patients. - The move could give the Doral-based practice a product business and a new source of differentiation in Miami’s aesthetic market. - The first products are expected to be included with high-ticket procedures, which could make the clinic’s take-home offering a key part of the patient experience. What happened: - Virginia Carneiro, founder of Vimaisamd in Doral, Florida, traveled to Munich, Germany, for CosmeticBusiness 2026. - CosmeticBusiness 2026 is a professional trade show focused on cosmetic formulation and private-label manufacturing. - Carneiro met with European manufacturers to start development of an exclusive post-treatment skincare line for Vimaisamd patients. - The trip was described as the first step in a broader plan to build clinic-owned intellectual property, a product line and national distribution. The details: - The planned skincare line is being developed to support results from Vimaisamd treatments, including Endolaser, HIFU and advanced body contouring protocols. - Carneiro said the goal is to help patients keep seeing progress at home after leaving the clinic. - Carneiro said the product concept does not yet exist in Miami and that Vimaisamd intends to be the first clinic in the market to offer it. - Vimaisamd has more than 350 five-star reviews and a 4.9 average rating since opening in Doral. - The clinic focuses on non-surgical aesthetic treatments and personalized treatment plans. - The line is currently in the development and supplier-selection phase. - The first products are expected to be post-facial and post-body treatment serums. - Full details are expected to be announced in the coming weeks. - The product line is expected to launch in late 2026. Between the lines: - The Munich trip signals a shift from service provider to brand builder for Vimaisamd. - The clinic appears to be using product development to deepen patient loyalty and create a more controlled treatment ecosystem. - If the line launches as planned, Vimaisamd could move into a more scalable business model that reaches beyond local procedures. What’s next: - Vimaisamd will continue selecting suppliers and refining the skincare formulas. - The clinic plans to share more product information in the coming weeks. - Patients should see the first launch in late 2026, starting with serums tied to facial and body procedures. - The clinic’s longer-term roadmap includes broader distribution beyond Miami.